Study ID: TV48125-CNS-30049 | 2015-004549-23

Study Title

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Teva Identifier

TV48125-CNS-30049 | 2015-004549-23

ClinicalTrials.gov Identifier

NCT02621931

Study Status

Completed

Trial Condition(s)

Migraine

Interventions

Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

March 22, 2016 - April 11, 2017

Phase

Phase 3

Study Type

Interventional